Evaluation of Overall Health State, Treatment Burden, and Satisfaction with Insulin Efsitora Alfa (Efsitora) vs. Daily Comparator in Adults with Type 2 Diabetes in the QWINT Clinical Trial Program

Key Points

• Treatment burden decreases significantly with insulin efsitora alfa compared to the daily comparator, enhancing patient satisfaction.
• In QWINT trials, 80% of adults reported improved overall health state when using efsitora alfa versus other insulin.
• Assessment included qualitative measures of treatment satisfaction over a six-month period among adults with type 2 diabetes.
• Improving satisfaction with efsitora alfa may lead to better adherence to diabetic management strategies.